ライフサイエンスコーパス: lost to follow-up

1 group, and followed for median 2.3 years (5% lost to follow-up).

2 ant), of which 37 were excluded (awaiting or lost to follow-up).

3 n-treatment related discontinuations (n = 10 lost to follow-up).

4 y with mRS scores of 0 or 1 (2 patients were lost to follow-up).

5 se of ineligibility and 14 participants were lost to follow-up).

6 tive at their 6-week follow-up visit (4 were lost to follow-up).

7 ccessful in 14 of 15 patients (1 patient was lost to follow-up).

8 strated 12 seroconversions (1 individual was lost to follow-up).

9 substantial improvement in 3 patients (1 was lost to follow-up).

10 ed 71 hard events over 24 +/- 7 months (0.2% lost to follow-up).

11 luded (intervention: 868, control: 858; 0.7% lost to follow-up).

12 One intervention cluster was lost to follow up.

13 Patient was subsequently lost to follow up.

14 count participants who had withdrawn or were lost to follow-up.

15 women in PM+ (25%) and 49 women in EUC (23%) lost to follow-up.

16 ied linkage to care status and 78 (10%) were lost to follow-up.

17 s were followed through to 24 months, with 1 lost to follow-up.

18 f any cause, and 3804 who emigrated and were lost to follow-up.

19 e-dose i.v.: n = 333); 139 participants were lost to follow-up.

20 uncture group and 13% in the sham group were lost to follow-up.

21 cipants did not proceed with surgery or were lost to follow-up.

22 2 children were lost to follow-up.

23 Ten patients were lost to follow-up.

24 ve the assigned treatment and the 5 who were lost to follow-up.

25 at less than 24 months, and six (4.7%) were lost to follow-up.

26 ot procedure related; p = 0.055), and 9 were lost to follow-up.

27 test, 33 died before follow-up and 167 were lost to follow-up.

28 ared gonorrhoea before treatment and 10 were lost to follow-up.

29 Four participants were lost to follow-up.

30 infants died or were stillborn and two were lost to follow-up.

31 Two patients in each group were lost to follow-up.

32 entire population, including those who were lost to follow-up.

33 vival) was 69.3 months, and 14 patients were lost to follow-up.

34 analysis included only children who were not lost to follow-up.

35 Two patients were lost to follow-up.

36 One participant was lost to follow-up.

37 me, 18 children (PQ arm: 7, PL arm: 11) were lost to follow-up.

38 onths, all patients were alive and none were lost to follow-up.

39 and 3,898 (11.3%) in the control group were lost to follow-up.

40 eat, excluding participants who died or were lost to follow-up.

41 Four patients (5%) were lost to follow-up.

42 No patients were lost to follow-up.

43 o-treat (n = 347), including 73 participants lost to follow-up.

44 Eight patients were lost to follow-up.

45 patients of group B became negative; one was lost to follow-up.

46 days in the matched cohort; no patients were lost to follow-up.

47 Three cases were lost to follow-up.

48 e imaging showed PD, and one participant was lost to follow-up.

49 nd of study, had the LVAD explanted, or were lost to follow-up.

50 ss, death, biopsy-proven acute rejection, or lost to follow-up.

51 Three patients were lost to follow-up.

52 stomosis, 2 died of other causes, and 3 were lost to follow-up.

53 s do not account for outcomes among patients lost to follow-up.

54 ere were 97 graft failures, 75 deaths, and 1 lost to follow-up.

55 transferred out of the program, and 34% were lost to follow-up.

56 an follow-up = 118 weeks; 29 (6%) women were lost to follow-up.

57 -up lasted 3 years, and <1% of patients were lost to follow-up.

58 p and 17 women in the cefpodoxime group were lost to follow-up.

59 No communities were lost to follow-up.

60 ollow-up and to describe individuals who are lost to follow-up.

61 s in 2005 were used for 61 patients who were lost to follow-up.

62 ollow-up was 1012 days, and no patients were lost to follow-up.

63 wo patients from each group were immediately lost to follow-up.

64 ween ages 3 months and 7 years, and 152 were lost to follow-up.

65 nfants died in the first 3 months and 8 were lost to follow-up.

66 rvival information for participants who were lost to follow-up.

67 home and 9 (2%) receiving facility care were lost to follow-up.

68 ion, 115 (31.9%) failed, and 83 (23.1%) were lost to follow-up.

69 unodeficiency syndrome, 49 died, and 90 were lost to follow-up.

70 ree and were censored on January 1, 1996, or lost to follow-up.

71 sent and thus was excluded from analyses and lost to follow-up.

72 years (0-11.3 years) with 21 patients (17%) lost to follow-up.

73 ned protocol, and two of these patients were lost to follow-up.

74 hieved a sustained viral response, and 1 was lost to follow-up.

75 ollow-up time was 325 days, 2 patients being lost to follow-up.

76 in the pitrakinra group dropped out or were lost to follow-up.

77 o were not given prophylaxis, and three were lost to follow-up.

78 n care, 21 (9%) were dead, and 24 (10%) were lost to follow-up.

79 gery, and there were no dropouts or patients lost to follow-up.

80 to continue the trial and 3219 children were lost to follow-up.

81 26 (0.3%) individuals dropped out or were lost to follow-up.

82 at death, at 56 days, or at last contact if lost to follow-up.

83 to 1 year of treatment with trastuzumab were lost to follow-up.

84 70 months); one patient with one lesion was lost to follow-up.

85 ndergone airway stent retrieval, and one was lost to follow-up.

86 nated because of adverse events, and one was lost to follow-up.

87 f referred potential live kidney donors were lost to follow-up.

88 rent age, 31 [SD, 7] years), of whom 18 were lost to follow-up.

89 sons tested were similar to those of persons lost to follow-up.

90 None was lost to follow-up.

91 66 patients, with eight (26%) of 31 patients lost to follow-up.

92 data were lacking because of patients being lost to follow-up.

93 .3%) of 166 patients, with 36 (26.7%) of 135 lost to follow-up.

94 er donation, 5 were asymptomatic, and 2 were lost to follow-up.

95 dary neoplasms, 81% were alive, and 14% were lost to follow-up.

96 mise, 672 pregnancy terminations and 87 were lost to follow-up.

97 164 (4%) were lost to follow-up.

98 Two patients were explanted and 1 lost to follow-up.

99 ly neonatal deaths were encountered and five lost to follow-up.

100 using the FI and FI minus number of patients lost to follow-up.

101 re followed for 180 days, and 71 (4.5%) were lost to follow-up.

102 FI that is lower than the number of patients lost to follow-up.

103 iabetic macular edema (DME), and temporarily lost to follow-up.

104 low-up of 48 months, whereas 2 patients were lost to follow-up.

105 lacked hospital outcomes and were considered lost to follow-up.

106 group and 10 (4%) in the control group were lost to follow-up.

107 25 (20%) were lost to follow-up.

108 5 participants were included, of whom 2 were lost to follow-up.

109 roup after parasite clearance and three were lost to follow-up.

110 93.5%) achieved SVR12, 6 relapsed, and 1 was lost to follow-up.

111 No patient was lost to follow-up.

112 , three withdrew from the study, and one was lost to follow-up.

113 w-up time exceeded 6 years, with no patients lost to follow-up.

114 treatments whereby 1 participant per arm was lost to follow-up.

115 One patient in each group was lost to follow-up.

116 sing imputation analyses that included those lost to follow-up.

117 One patient was lost to follow-up.

118 -week follow-up period, 35 (9%) died or were lost-to-follow-up.

119 ieved cure or probable cure, 29 (13.7%) were lost to follow-up, 10 (4.7%) experienced treatment failu

120 e-year post surgery, less RYGB-patients were lost-to follow-up (12.1% vs 16.5%, P < 0.001) and RYGB r

121 Including deaths and those lost to follow up, 15 (13.2%) were non-practicing; 5 vol

122 d follow-up, 11% withdrew early, and 4% were lost to follow-up; 19% discontinued their regimen premat

123 hs, eight participants had withdrawn or were lost to follow-up, 280 (94%) individuals provided primar

124 Attrition was low with 55 children lost to follow up (3.4%) and no school dropout.

125 Seven eyes were lost to follow-up, 4 eyes abandoned wearing the scleral

126 Three patients were lost to follow-up, 4 patients died from complications of

127 stational age of 27+/-6 weeks, there were 11 lost to follow-up (5%), 15 terminations (6%), and 41 dem

128 Only 153 (5%) children were lost to follow-up (76 in the co-trimoxazole group and 77

129 We identified a random sample of patients lost to follow-up (9 months without a visit).

130 ted follow-up, 7% stopped early, and 9% were lost to follow-up; 9% discontinued their regimen early.

131 ecember 2010, nine (5%) of 211 patients were lost to follow-up; 94 (45%) of 211 are alive and 88 (94%

132 5780 patients (17%) were lost to follow-up, 991 (17%) were selected for tracing b

133 the intervention group and 20 controls were lost to follow-up; a further ten women assigned to the i

134 No eyes were lost to follow-up after 12 months.

135 clinic in Uganda, where 29% of patients were lost to follow-up after 2 years (January 1, 2004-Septemb

136 ontrol persisted in 13 of 40 participants (2 lost to follow-up after 24 weeks), whereas functional cu

137 patients had viral relapse; one patient was lost to follow-up after achieving sustained virological

138 single patient who did not achieve SVR12 was lost to follow-up after achieving SVR4.

139 3.7%) completed the study and 21 (5.9%) were lost to follow-up after completing protocol therapy.

140 ies, six improved spontaneously, and one was lost to follow-up after exposure stopped.

141 ir, and GS-9451 for 6 weeks (one patient was lost to follow-up after reaching sustained viral respons

142 euronal ceroid lipofuscinosis; one child was lost to follow-up after the first visit and nine patient

143 age 4A, 4B, and 5) at presentation and those lost to follow-up after treatments were excluded.

144 After randomization, 4 patients were lost to follow-up, all after month 18, and 1 withdrew du

145 nsferred back to the referring physician and lost to follow-up, all patients with reported pulmonary

146 None was lost to follow-up, although 20 discontinued intervention

147 f 5.9 years, 17.8% developed PAD, 13.0% were lost to follow-up and 11.1% died.

148 group), but at the 10-year follow-up 14 were lost to follow-up and 12 withdrew, leaving 3031 to enter

149 up) were contacted, whereas 18 patients were lost to follow-up and 20 patients had died.

150 304 patients without SVR12 results, 48 were lost to follow-up and 256 had no SVR12 results but clini

151 A total of 3.1% of patients were lost to follow-up and 3.2% of patients withdrew consent.

152 Among 18 081 patients, 3150 (18%) were lost to follow-up and 579 (18%) were traced.

153 were excluded, and 70 without follow-up--63 lost to follow-up and 7 new to the study--were excluded

154 One patient was lost to follow-up and died after 240 days of support.

155 mal ECG, different cardiac diseases, or were lost to follow-up and exited the study.

156 We traced a random sample of patients lost to follow-up and incorporated updated information i

157 822 patients were lost to follow-up and not included in the main analysis;

158 ue with follow-up visits, or 2) patients are lost to follow-up and their outcome data are missing.

159 and three patients in the placebo group were lost to follow-up and therefore discontinued before stud

160 40 patients were lost to follow-up and were censored.

161 tant tuberculosis treatment, excluding those lost to follow up, and was stratified by ART use.

162 Two patients relapsed, 2 were lost to follow-up, and 1 withdrew consent.

163 Of 1,609 children, 4 died, 61 were lost to follow-up, and 119 were transferred out due to s

164 At 6 months, 51 patients were lost to follow-up, and 17 were alive with unknown status

165 ere in the reference group, 8% (n = 46) were lost to follow-up, and 2% (n = 12) died without POD less

166 n 4 states: 1) suppressed, 2) detectable, 3) lost to follow-up, and 4) deceased.

167 echnetium-99m sestamibi MPS, 254 (4.1%) were lost to follow-up, and 586 with early revascularization

168 g did not receive the study drug and one was lost to follow-up, and one patient assigned to receive p

169 4 weeks after the end of treatment but were lost to follow-up, and one was reinfected.

170 None were lost to follow-up, and serial echocardiography was obtai

171 number of individuals with PLC, participants lost to follow-up, and the large proportion of participa

172 of events in each group, number of patients lost to follow-up, and trial characteristics, were extra

173 vailable for 406 (64%) participants, 25 were lost to follow-up, and two participants no longer wanted

174 icipants in the standard care group had been lost to follow-up, and were censored at their last visit

175 ned from tracing a random subset of patients lost to follow-up as of July 31, 2015.

176 ents met criteria for analysis (38 eyes were lost to follow up at 3 months; 68 at 12 months; 146 at 6

177 Thirteen percent were lost to follow-up at 1 year, and 30% at 2 years after su

178 xperienced virologic relapse, and 1 (2%) was lost to follow-up at 4 weeks after treatment.

179 s and 19% of control group participants were lost to follow-up at 6 months.

180 blation with biventricular pacing; none were lost to follow-up at 6 months.

181 Three patients were lost to follow-up at 63, 39, and 4 months after treatmen

182 ve survived to 36-months postinjury but were lost to follow-up at all time points.

183 On average, studies have 30% of patients lost to follow-up at the stated end-point.

184 On average, 31% were lost to follow-up at the study's end.

185 from the APBI group withdrew consent or were lost to follow-up at this stage, so 2039 and 2093 patien

186 ued (one withdrew consent at week 8, one was lost to follow-up at week 12).

187 Five patients were lost to follow-up because of emigration (99.9% follow-up

188 60 patients died and three patients were lost to follow up before the 6-month analysis.

189 Nine patients discontinued treatment or were lost to follow-up before completion; 1 is continuing DAA

190 Eight mothers were lost to follow-up before delivery.

191 ncope recurrences, and only 14 patients were lost to follow-up before syncope recurrence.

192 were excluded from the analysis if they were lost to follow-up before the end of first trimester.

193 the imiquimod group either withdrew or were lost to follow-up before the first 6-week safety assessm

194 was not known for 143 (1%) patients who were lost to follow-up (benazepril plus amlodipine, n=70; ben

195 He was then lost to follow-up but later was seen with worsening atax

196 Two practices were lost to follow-up but provided some outcome data.

197 Two patients were lost to follow-up, but were included in analyses.

198 5 patients (four for mortality outcome) were lost to follow-up by June 30, 2015.

199 15,270 patients were deemed lost to follow-up by the end of the study.

200 Six women were lost to follow-up; data from 655 were analyzed (325 in t

201 ) analysis assumed all participants who were lost to follow-up, died, or stopped ART as having virolo

202 Four patients were lost to follow-up during the clinical follow-up.

203 e candidates were excluded because they were lost to follow-up during the fitting process.

204 ons were required, nor were any participants lost to follow-up during the investigation.

205 No patients died or were lost to follow-up during the study.

206 78 participants were withdrawn or lost to follow-up during the study; thus, the per-protoc

207 wedish registers, with basically no patients lost to follow-up during up to 7 years after surgery.

208 ustained virologic response at 12 weeks were lost to follow-up either during or after treatment.

209 incorporation of outcomes from the patients lost to follow-up, estimated 3 year mortality increased

210 ulation every 5 years, and re-engaging those lost to follow-up every 5 years.

211 esults, particularly when number of patients lost to follow-up exceeds FI.

212 n who consented for ancillary KEEPS-Cog were lost to follow-up for cognitive assessment (3MS and cogn

213 None of the patients were lost to follow-up for the main outcome.

214 participants who withdrew and three who were lost to follow-up from the AQ-13 group, did not meet the

215 No patient was lost to follow-up (>/= 12 months in all patients).

216 re infected with HIV and on ART and who were lost to follow-up (>90 days late for last scheduled visi

217 analysis assuming that 60% of the population lost to follow-up had died gave 3000 additional deaths,

218 m 17,602 (17%) were lost to follow-up: Those lost to follow-up had median age 36 years, 60% were fema

219 Because many of these ACHD patients are lost to follow-up in adulthood, pregnancy represents a t

220 ient each in arms B and C (two patients were lost to follow-up in arm C).

221 Two patients were lost to follow-up in complete remission at 12 months.

222 in the ART stage; 2247 (3.9%) patients were lost to follow-up in pre-ART stage and 2847 (2.2%) lost

223 No patients dropped out or were lost to follow-up in study 1; in study 2, two patients i

224 Patients lost to follow-up in the first year were excluded.

225 Three participants were lost to follow-up in the FMT group.

226 99%) of 518 patients (five participants were lost to follow-up in the intervention group and one in t

227 that death is a cause of being classified as lost to follow-up in this setting, revealed "collider" b

228 A total of 1685 patients (13.36%) were lost to follow-up, leaving 11,821 patients (86.64%) for

229 Three participants in each group were lost to follow-up, leaving 247 analysed per group.

230 Of 63 randomized patients, 3 were lost to follow-up, leaving 39 TF and 21 COP for analyses

231 t for participation in the trial or who were lost to follow-up, leaving a total of 680 patients, a fa

232 four South African cohorts in which patients lost to follow-up (LTF) could be linked to the national

233 f outcomes among a random sample of patients lost to follow up (LTFU) from 32 clinics in Zambia to un

234 tensively traced a random sample of patients lost to follow-up (LTFU) and incorporated tracing outcom

235 ciency virus (HIV)-infected patients who are lost to follow-up (LTFU) on reengagement has not been ri

236 treated immediately, the baseline proportion lost to follow-up (LTFU), and the average treatment dela

237 ng death rates among adult patients who were lost to follow-up (LTFU).

238 acing a multistage random sample of patients lost to follow-up (LTFU, >90 days late for last appointm

239 World Health Organization (WHO) targets for lost-to-follow-up (LTFU), ART prescribing practices, and

240 randomly assigned participants who were not lost to follow-up (modified full-analysis set) and in pa

241 mes heart or heterotaxy syndrome or who were lost to follow-up (n = 24) were excluded.

242 analysis for non-virological reasons (death, lost-to-follow-up [n=2], non-compliance, patient withdra

243 irin arm and the 16-week plus ribavirin arm (lost to follow-up, n = 1), respectively.

244 The FI and FI minus number of patients lost to follow-up of RCTs supporting the 2012 American C

245 Nine children were lost to follow-up (one in chloramphenicol group; eight i

246 n, severe pre-existing comorbidity], one was lost to follow-up, one developed of Graves disease, and

247 Participants who were lost to follow-up or did not provide biochemical validat

248 43 patients were lost to follow-up or discontinued the assigned intervent

249 g women, 40 women (22 iron, 18 placebo) were lost to follow-up or excluded at birth; 12 mothers were

250 Nine women were lost to follow-up or had elective termination.

251 omen, were assessed; 32 treatment cases were lost to follow-up or lost owing to death.

252 h CD4 less than 100 cells per muL on ART but lost to follow-up or with virological failure.

253 ived treatment (data were censored for those lost-to-follow-up or who died).

254 ients (18%) with unfavorable outcomes (died, lost to follow-up, or stopped treatment).

255 mposite event of known death from any cause, lost to follow-up, or transfer to estimate worst-case mo

256 riteria, interventions, numbers enrolled and lost to follow-up, outcome ascertainment, and results we

257 4 count 550 cells/microL), 1294 (20%) became lost to follow-up over 2.5 years.

258 nd 112 (7%) participants, respectively, were lost to follow-up over median 4.9 years' follow-up.

259 on-to-treat basis with participants who were lost to follow-up (patch alone [n = 13] and combination

260 etheless be needed to minimize the number of lost to follow-up patients between baseline and follow-u

261 From this cohort, we identified lost-to-follow-up patients (defined as 90 or more days l

262 low-up or excluded at birth; 12 mothers were lost to follow-up postpartum (5 iron, 7 placebo).

263 ectively terminated their pregnancy, 12 were lost to follow-up prior to completion of pregnancy, and

264 s' in a complex health care system: becoming lost to follow-up, receiving inadequate care, or requiri

265 ients resumed continuous IM and all but one (lost to follow-up) regained CCgR and MMR.

266 year, 26 (9%) and 50 (18%) participants were lost to follow-up, respectively.

267 Seven women were lost to follow-up, six withdrew consent, one died, and t

268 1%) women in the revealed testing group were lost to follow-up, so 573 (99%) women in this group were

269 Five participants were lost to follow-up, so the primary analysis included 81 p

270 Although many patients are lost to follow-up, the evidence indicates that subthalam

271 Among 743 NP patients, 64 died, 13 were lost to follow up; therefore, a total of 666 patients we

272 Given the proportion of patients lost to follow up, these findings merit further confirma

273 not return their case report forms and were lost to follow-up; these patients were not included in o

274 y-evaluable population, which excluded women lost to follow-up, those aged over 35 years, women with

275 104,966 patients, of whom 17,602 (17%) were lost to follow-up: Those lost to follow-up had median ag

276 Only seven women were lost to follow-up through December 2005.

277 3%) prematurely discontinued therapy or were lost to follow-up; thus, sustained response rates with p

278 suming varying proportions of the population lost to follow-up to be dead.

279 raced a random sample with unknown outcomes (lost to follow-up) to document true care status and HIV

280 cohort, through September 1, 2013 (with 1.1% lost to follow-up), to address whether there is a relati

281 ) and the median FI minus number of patients lost to follow-up was 1.0 (95% CI, 0.0-3.0).

282 The analysis in which lost to follow-up was assigned to failure yielded a risk

283 In 37 trials (30.1%), number of patients lost to follow-up was higher than the FI.

284 The number of patients lost to follow-up was observed at different time points.

285 -up but including those who withdrew or were lost to follow-up, we assessed 80 of 99 patients (81%) a

286 Patients lost to follow-up were censored on the date of their las

287 vents such as graft loss, patient death, and lost to follow-up were censored.

288 e intent-to-treat approach in which patients lost to follow-up were considered as having clinical cur

289 e intent-to-treat approach in which patients lost to follow-up were considered as having not responde

290 After patients lost to follow-up were excluded, the study population wa

291 Subjects lost to follow-up were more likely than those retained t

292 ts were obtained when participants that were lost to follow-up were treated as smokers (268 [9%] of 2

293 ithdrew consent during the trial, and 4 were lost to follow up, which left 798 participants in the as

294 More African American donor referrals are lost to follow-up while rates of other reasons were simi

295 rt of 50 patients (6 with incomplete data or lost to follow-up) with acute second-degree burns from a

296 opulation, excluding those patients who were lost to follow-up, with an equivalency test on the basis

297 ntly more eyes in the aflibercept group were lost to follow-up within 12 months (21% vs. 9% ranibizum

298 imultaneous nonkidney transplants, death, or lost to follow-up within 90 days were excluded, unless a

299 1,388 baseline participants died and 81 were lost to follow-up, yielding 11,833 person-years of obser

300 Accounting for outcomes among those lost to follow-up yields a more informative assessment o